[go: up one dir, main page]

MX2022006229A - Composiciones y metodos para el tratamiento de resistencia a la insulina. - Google Patents

Composiciones y metodos para el tratamiento de resistencia a la insulina.

Info

Publication number
MX2022006229A
MX2022006229A MX2022006229A MX2022006229A MX2022006229A MX 2022006229 A MX2022006229 A MX 2022006229A MX 2022006229 A MX2022006229 A MX 2022006229A MX 2022006229 A MX2022006229 A MX 2022006229A MX 2022006229 A MX2022006229 A MX 2022006229A
Authority
MX
Mexico
Prior art keywords
insulin resistance
treatment
compositions
methods
insulin
Prior art date
Application number
MX2022006229A
Other languages
English (en)
Inventor
Salim Merali
Carlos A Barrero
Wayne E Childers
George C Morton
Original Assignee
Univ Temple
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Temple filed Critical Univ Temple
Publication of MX2022006229A publication Critical patent/MX2022006229A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Los compuestos de la fórmula I, y sales farmacéuticamente efectivas del mismo (ver Fórmula) en donde R1 - R14, m, n, o, p, q y r son como se definen en la presente, se proporcionan para el tratamiento de incrementar la sensibilidad a la insulina, reducir la resistencia a la insulina, prevenir la resistencia a la insulina y tratar los trastornos de resistencia a la insulina.
MX2022006229A 2016-09-07 2019-03-06 Composiciones y metodos para el tratamiento de resistencia a la insulina. MX2022006229A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662384390P 2016-09-07 2016-09-07

Publications (1)

Publication Number Publication Date
MX2022006229A true MX2022006229A (es) 2022-06-22

Family

ID=61561578

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019002607A MX392555B (es) 2016-09-07 2017-09-07 Composiciones y métodos para el tratamiento de resistencia a la insulina.
MX2022006229A MX2022006229A (es) 2016-09-07 2019-03-06 Composiciones y metodos para el tratamiento de resistencia a la insulina.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019002607A MX392555B (es) 2016-09-07 2017-09-07 Composiciones y métodos para el tratamiento de resistencia a la insulina.

Country Status (9)

Country Link
US (2) US10729670B2 (es)
EP (2) EP3509575B1 (es)
JP (1) JP7235312B2 (es)
CN (1) CN110139644B (es)
AU (3) AU2017324510B2 (es)
BR (1) BR112019004405A2 (es)
MX (2) MX392555B (es)
WO (1) WO2018049019A1 (es)
ZA (1) ZA201902155B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019004405A2 (pt) * 2016-09-07 2020-06-23 Temple University - Of The Commonwealth System Of Higher Education Compostos e seus usos para aumentar a sensibilidade à insulina, reduzir a resistência à insulina e/ou prevenir a resistência à insulina e para tratar um distúrbio de resistência à insulina e composição os compreendendo
BR112020018010A2 (pt) * 2018-03-07 2020-12-29 Temple University - Of The Commonwealth System Of Higher Education Métodos de prevenção ou tratamento de diabetes tipo 2, de prevenção ou tratamento de pré-diabetes e de prevenção ou tratamento de uma condição em um indivíduo em necessidade
JP2021517125A (ja) * 2018-03-07 2021-07-15 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイションＴｅｍｐｌｅ Ｕｎｉｖｅｒｓｉｔｙ−Ｏｆ Ｔｈｅ Ｃｏｍｍｏｎｗｅａｌｔｈ Ｓｙｓｔｅｍ Ｏｆ Ｈｉｇｈｅｒ Ｅｄｕｃａｔｉｏｎ インスリン抵抗性を治療するための組成物および方法
TW202206062A (zh) 2020-04-24 2022-02-16 美國坦普大學 高等教育聯邦系統 治療非酒精性脂肪肝炎的方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5344846A (en) 1992-12-30 1994-09-06 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for inhibiting deoxyhypusine synthase and the growth of cells
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
IT1283218B1 (it) * 1996-03-08 1998-04-16 Bracco Spa Polichelanti, loro complessi con ioni metallici, loro preparazione e loro usi
IL140844A0 (en) 2001-01-10 2002-02-10 Polygene Ltd Cationic polysaccharide compositions
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US20080260703A1 (en) 2007-04-23 2008-10-23 Medistem Labortories Treatment of Insulin Resistance and Diabetes
EP3103467A1 (en) 2008-02-07 2016-12-14 Cornell University Methods for preventing or treating insulin resistance
JP2013516442A (ja) * 2010-01-07 2013-05-13 アクロン・モレキュールズ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 肥満症に用いる小分子
KR101982491B1 (ko) 2011-08-30 2019-05-27 아카데미쉬 메디쉬 센트륨 인슐린 저항 예방 및/또는 치료 방법
AU2012325072B2 (en) 2011-10-18 2015-12-03 Société des Produits Nestlé S.A. Composition for use in increasing insulin sensitivity and/or reducing insulin resistance
WO2014062794A1 (en) 2012-10-17 2014-04-24 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods for improving glucose uptake
US20150182483A1 (en) * 2014-01-02 2015-07-02 Joel Steven Goldberg Glycation of l-lysine to lower blood glucose and treat complications of diabetes
CN103833623B (zh) * 2014-03-03 2016-07-06 河南大学 一种氨基酸-胺缀合物及其制备方法和应用
WO2015161448A1 (en) * 2014-04-22 2015-10-29 Wuhan Ll Science And Technology Development Co., Ltd. Ornithine-containing or aspartate-containing compositions and the uses thereof
US10272106B2 (en) * 2014-06-04 2019-04-30 Case Western Reserve University Compositions and methods of treating diabetic retinopathy
US10947350B2 (en) 2015-09-13 2021-03-16 The Research Foundation For The State University Of New York Functional, segregated, charged telodendrimers and nanocarriers and methods of making and using same
EP3463330B1 (en) 2016-06-02 2022-05-04 Syndromex Ltd. Diabetes treatment regimens using alpha, alpha-substituted long-chain amphipathic carboxylates
BR112019004405A2 (pt) * 2016-09-07 2020-06-23 Temple University - Of The Commonwealth System Of Higher Education Compostos e seus usos para aumentar a sensibilidade à insulina, reduzir a resistência à insulina e/ou prevenir a resistência à insulina e para tratar um distúrbio de resistência à insulina e composição os compreendendo
JP2021517125A (ja) 2018-03-07 2021-07-15 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイションＴｅｍｐｌｅ Ｕｎｉｖｅｒｓｉｔｙ−Ｏｆ Ｔｈｅ Ｃｏｍｍｏｎｗｅａｌｔｈ Ｓｙｓｔｅｍ Ｏｆ Ｈｉｇｈｅｒ Ｅｄｕｃａｔｉｏｎ インスリン抵抗性を治療するための組成物および方法
BR112020018010A2 (pt) 2018-03-07 2020-12-29 Temple University - Of The Commonwealth System Of Higher Education Métodos de prevenção ou tratamento de diabetes tipo 2, de prevenção ou tratamento de pré-diabetes e de prevenção ou tratamento de uma condição em um indivíduo em necessidade
CN112955143B (zh) 2018-09-18 2023-10-13 北京强新生物科技有限公司 非酒精性脂肪性肝病的治疗

Also Published As

Publication number Publication date
JP2019526600A (ja) 2019-09-19
EP3509575B1 (en) 2025-03-19
CA3035972A1 (en) 2018-03-15
AU2023274183A1 (en) 2023-12-21
US10729670B2 (en) 2020-08-04
ZA201902155B (en) 2023-12-20
CN110139644A (zh) 2019-08-16
WO2018049019A1 (en) 2018-03-15
AU2017324510B2 (en) 2023-08-31
JP7235312B2 (ja) 2023-03-08
US11596615B2 (en) 2023-03-07
AU2017324510A1 (en) 2019-04-11
CN110139644B (zh) 2023-05-23
AU2025238063A1 (en) 2025-10-23
EP4595969A3 (en) 2025-10-22
EP3509575A4 (en) 2020-04-22
EP3509575A1 (en) 2019-07-17
MX392555B (es) 2025-03-24
US20210046030A1 (en) 2021-02-18
MX2019002607A (es) 2019-09-18
BR112019004405A2 (pt) 2020-06-23
US20190192462A1 (en) 2019-06-27
EP4595969A8 (en) 2025-09-10
EP4595969A2 (en) 2025-08-06

Similar Documents

Publication Publication Date Title
ZA202001717B (en) Compounds, salts thereof and methods for treatment of diseases
PH12019501321A1 (en) Methods of treating or preventing cholesterol related disorders
MX395482B (es) Compuestos antiproliferativos y metodos de uso de los mismos
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
MX2018000396A (es) Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4).
GEP20186933B (en) Substituted dihydroisoquinoline compounds
PH12021551134A1 (en) Oxysterols and methods of use thereof
CY1122805T1 (el) Ενωσεις και μεθοδοι για την αγωγη βακτηριακων λοιμωξεων
PH12018500061A1 (en) Oxysterols and methods of use thereof
TN2017000075A1 (en) Compounds and compositions as raf kinase inhibitors
MX2021014531A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
MX2017017171A (es) Compuestos terapeuticos y composiciones para el tratamiento de trastornos sociales y trastornos de uso de sustancias.
PH12017500653A1 (en) Substituted benzothiophenyl derivatives as gpr40 agonists for the treatment of type ii diabetes
MX2022006229A (es) Composiciones y metodos para el tratamiento de resistencia a la insulina.
MY202127A (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
MX2018007517A (es) Compuestos triciclicos y composiciones como inhibidores de quinasa.
WO2019040104A3 (en) COMPOUNDS, RELATED SALTS AND METHODS OF TREATING DISEASES
PH12017501560A1 (en) Tetrahydropyranyl benzamide derivatives
TH104715B (th) สารประกอบและวิธีการสำหรับการรักษาการติดเชื้อแบคทีเรีย
MX2016009250A (es) Nuevos imidazoles para el tratamiento y profilaxis de la infeccion por virus sincicial respiratorio.
JO3477B1 (ar) مركبات أحادي باكتام عضوية لعلاج العدوى البكتيرية